Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells

Journal of Immunology

Volumn 165, Issue 7, 2000, Pages 4133-4140

  Meyer zum Buschenfelde C ^a   Nicklisch, N ^a   Rose John, S ^a   Peschel, C ^a   Bernhard, H ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; LYMPHOCYTE CLONE; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; RETROVIRUS; STEM CELL; TUMOR REJECTION;

EID: 0034292371     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.7.4133     Document Type: Article

References (72)

1. Prospects for adoptive T cell therapy
2. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
3. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
4. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy
5. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
6. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus specific T lymphocytes
7. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease
8. Human tumor antigens recognized by T lymphocytes
9. T cell defined tumor antigens
10. Serological identification of human tumor antigens
11. A new era for cancer immunotherapy based on the genes that encode cancer antigens
12. The makings of a tumor rejection antigen
13. HER-2/neu oncogenic protein: Issues in vaccine development
14. Amplification of c-erbB-2 and aggressive human breast tumors?
15. Expression of HER-2/neu proto-oncogene in normal human adult and fetal tissues
16. Stability of HER-2/neu expression over time and at multiple metastatic sites
17. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer
18. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
19. Cylotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene
20. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
21. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes
22. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
23. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
24. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
25. erb B-2 is a potent oncogene when overexpressed in NIH/3T3 cells
26. Inverse relationship of melanocyte differentiation antigen expression in melanome tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
27. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
28. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein
29. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
30. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
31. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
32. Dendritic cells and the control of immunity
33. Dendritic cells: Unique leukocyte populations which control the primary immune response
34. Cellular immune response to human renal cell carcinomas: Definition of a common antigen recognized by HLA-A2-restricted cytotoxic T lymphocytes (CTL) clones
35. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serumfree conditions
36. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
37. Construction and use of safe and efficient amphotropic packing cell line
38. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood
39. A bioactive designer cytokine for human hematopoietic progenitor cell expansion
40. Retrovitally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity
41. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1)
42. Retrovital transduction of human dendritic cells with a tumor-associated antigen gene
43. + Hodgkin's disease
44. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus
45. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanome and viral peptide antigens
46. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and upregulated by interferon-γ
47. Cellular immune response to human renal cell carcinomas: Definition of a common antigen recognized by HLA-A2-restricted cytotoxic T lymphocytes (CTL) clones
48. The gp 130-stimulating designer cytokine Hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells
49. Cancer vaccines
50. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
51. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo
52. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus
53. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α
54. Soluble receptors for cytokines and growth factors: Generation and biological function
55. Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression
56. + cells
57. TGF-β1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis
58. GM-CSF and TNFα cooperate in the generation of dendritic Langerhans cells
59. + progenitors in human bone marrow
60. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
61. + bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α
62. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability
63. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
64. Serum-free culture conditions for the in vitro generation of dendritic cells from peripheral blood CD34 positive progenitor cells of human adults
65. + peripheral blood dendritic cells are differentially regulated by cytokines
66. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion·
67. + dendritic cells using recombinant adenovirus suppressed T-cell stimulatory capacity
68. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
69. Different MHC class I alleles compete for presentation of overlapping viral epitopes
70. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
71. + tumors
72. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific CTL